A prodrug strategy for the oral delivery of a poorly soluble HCV NS5B thumb pocket 1 polymerase inhibitor using self-emulsifying drug delivery systems (SEDDS).

Abstract A prodrug approach was developed to address the low oral bioavailability of a poorly soluble ( 36 (mp 161 °C) showed good solubility in individual SEDDS components (up to 80 mg/mL) compared to parent 2 (